Reference
- Geleris J, Sun Y, Platt J, et al. Observational study of hydroxychloroquine in hospitalized patients with COVID-19. N Engl J Med. 2020 May 7. [Epub ahead of print]
Gene Emery |
Reference
Handpicked Reviews of Contemporary Literature
The Johns Hopkins Lupus Center, Baltimore, has described its experience using hydroxychloroquine (HCQ) levels.1 Forty-four percent of its patients had levels below 500 ng/mL (partial nonadherence); 13% were severely nonadherent (<200 ng/mL). They were shown their results and educated on HCQ adherence. Adherence then improved to 80%; those with lower HCQ levels had higher disease…
CHICAGO—The correct dosing of hydroxychloroquine (HCQ) for systemic lupus erythematosus (SLE) is a concern of all rheumatologists. Petros Efthimiou, MD, clinical professor of medicine at New York University, New York City, opened the Great Debate of the 2018 ACR/ARHP Annual Meeting by stating, “Today, we will be discussing a critical clinical problem that affects everyone’s…
Hydroxychloroquine (HCQ) is nearly universally recommended for pregnant patients with systemic lupus erythematosus (SLE) to reduce lupus disease activity and adverse outcomes in pregnancy.1-3 Yet despite strong evidence supporting its benefits, HCQ appears underutilized, with several studies suggesting fewer than half of all women with lupus take this medication during pregnancy.4 How accurately these results…